These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9855533)

  • 21. Extended-release carbamazepine capsules : in bipolar I disorder.
    Swainston Harrison T; Keating GM
    CNS Drugs; 2005; 19(8):709-16. PubMed ID: 16097852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
    Miller AD; Krauss GL; Hamzeh FM
    Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
    Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
    Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation.
    Nag D; Garg RK; Agarwal A
    J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.
    Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M
    Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Exacerbation of complex partial seizures by carbamazepine in a child with frontal lobe epilepsy].
    Enoki H; Ohtahara S
    No To Hattatsu; 1995 Sep; 27(5):403-5. PubMed ID: 7576788
    [No Abstract]   [Full Text] [Related]  

  • 27. [The assessment of lamotrigine effectiveness in patients with drug-resistant epilepsy].
    Małowidzka-Serwińska M
    Neurol Neurochir Pol; 1998; 32(2):285-93. PubMed ID: 9760548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New formulations of drugs in epilepsy.
    Wheless JW; Venkataraman V
    Expert Opin Pharmacother; 1999 Nov; 1(1):49-60. PubMed ID: 11249564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
    Powell G; Saunders M; Marson AG
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome evaluation of gabapentin as add-on therapy for partial seizures. "NEON" Study Investigators Group. Neurontin Evaluation of Outcomes in Neurological Practice.
    Bruni J
    Can J Neurol Sci; 1998 May; 25(2):134-40. PubMed ID: 9604135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
    Garnett WR; Gilbert TD; O'Connor P
    Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Possible induction of West syndrome by oxcarbazepine therapy in a patient with complex partial seizures.
    Veerapandiyan A; Singh P; Mikati MA
    Epileptic Disord; 2012 Mar; 14(1):99-103. PubMed ID: 22425652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy.
    Lee BI; No SK; Yi SD; Lee HW; Kim OJ; Kim SH; Kim MK; Kim SE; Kim YS; Kim JM; Lee SJ; Shin DJ; Park SP; Kim YI; Heo K; Cho YW; Cho YJ; Kim YN
    Seizure; 2018 Feb; 55():17-24. PubMed ID: 29324401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of adverse events and quality of life in epilepsy: design of a new community-based trial.
    Privitera M; Ficker DM
    Epilepsy Behav; 2004 Dec; 5(6):841-6. PubMed ID: 15582830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-release formulations for the treatment of epilepsy.
    Bialer M
    CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetaminophen toxicity with concomitant use of carbamazepine.
    Jickling G; Heino A; Ahmed SN
    Epileptic Disord; 2009 Dec; 11(4):329-32. PubMed ID: 19995690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
    Konsil J; Dechasathian S; Mason DH; Stevens RE
    J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of add-on divalproex sodium in the treatment of complex partial seizures. The M88-194 Study Group.
    Willmore LJ; Shu V; Wallin B
    Neurology; 1996 Jan; 46(1):49-53. PubMed ID: 8559420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preliminary evaluation of early results of the treatment of epilepsy in children with delayed-action carbamazepine].
    Losiowski Z; Czochañska J; Zimak J
    Neurol Neurochir Pol; 1992; 26(4):571-2. PubMed ID: 1484585
    [No Abstract]   [Full Text] [Related]  

  • 40. Complex partial seizures and aphasia as initial manifestations of non-ketotic hyperglycemia. Case report.
    Batista MS; Silva DF; Ferraz HB; de Andrade LA
    Arq Neuropsiquiatr; 1998 Jun; 56(2):296-9. PubMed ID: 9698744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.